ACRPO  >> Vol. 4 No. 3 (July 2015)

    1例晚期胃癌患者的循证治疗
    Evidence-Based Treatment for 1 Case with Advanced Gastric Cancer Patients

  • 全文下载: PDF(978KB) HTML   XML   PP.20-25   DOI: 10.12677/ACRPO.2015.43004  
  • 下载量: 1,657  浏览量: 5,429  

作者:  

江平,王崇高,胡昇庠,张增岭,胡伟,桂德春:南京市浦口区中心医院普通外科,江苏 南京

关键词:
胃癌晚期循证治疗Gastric Cancer Advanced Evidence-Based Treatment

摘要:

目的:采用循证医学方法为1例晚期胃癌患者制定诊治方案。方法:根据临床问题检索MEDLINE、ACP Journal Club、中国知网,并利用搜索引擎——谷歌学术搜索在互联网所获取的文献进行归纳分析。结果:共获得有关晚期胃癌姑息手术和新辅助化疗时机的系统评价6篇,临床对照研究病例756例。以上证据表明:晚期胃癌行新辅助化疗的根治性手术率及生存率优于姑息手术组。结合客观证据及患者意愿,为患者实施了两个疗程的奥沙利铂+希罗达(Cape + OX)化疗方案,结合化疗前后病灶的影像学变化,成功实施了手术,无手术后并发症发生。结论:循征医学方法对疑难病例的治疗有一定的指导作用。

Objective: To make the diagnosis and treatment for advanced gastric cancer patients using evi-dence-based medicine method. Methods: Retrievalling MEDLINE, ACP Journal Club, Chinese How-Net according to the clinical question, and then searching and summarizing the literature in Internet using the search engines—Google academic search. Results: 6 systematic reviews about advanced gastric cancer palliative operation and neoadjuvant chemotherapy time and 756 cases of controlled clinical study were obtained. The above evidence approved that it was superior to palliative operation group in the radical surgery and survival rates. Combining the objective evidence and the patients’ willingness, patients were treated with two courses of chemotherapy options with oxaliplatin plus capecitabine (Cape + OX) regimen. The operation was performed successfully without complications combining with the change of focus images before and after chemotherapy. Conclusion: The evidence-based medicine method was useful for the treatment of difficult patients.


文章引用:
江平, 王崇高, 胡昇庠, 张增岭, 胡伟, 桂德春. 1例晚期胃癌患者的循证治疗[J]. 亚洲肿瘤科病例研究, 2015, 4(3): 20-25. http://dx.doi.org/10.12677/ACRPO.2015.43004

参考文献

[1] Acín-Gándara, D., Pereira-Pérez, F., Castaño-Pascual, A., et al. (2012) Gastrointestinal stromal tumors: Diagnosis and treatment. Cirugía y Cirujanos, 80, 44-51.
[2] Nagasako, Y., Satoh, S., Isogaki, J., et al. (2012) Impact of anastomotic complications on outcome after laparoscopic gastrectomy for early gastric cancer. British Journal of Surgery, 99, 849-854.
http://dx.doi.org/10.1002/bjs.8730
[3] Lorenzen, S., Blank, S., Lordick, F., et al. (2012) Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Annals of Surgical Oncology, 19, 2119-2127.
http://dx.doi.org/10.1245/s10434-012-2254-1
[4] Bornschein, J., Rokkas, T., Selgrad, M., et al. (2011) Gastric cancer: Clinical aspects, epidemiology and molecular background. Helicobacter, 16, 45-52.
http://dx.doi.org/10.1111/j.1523-5378.2011.00880.x
[5] Blank, S., Bläker, H., Schaible, A., et al. (2012) Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbeck’s Archives of Surgery, 397, 45-55.
http://dx.doi.org/10.1007/s00423-011-0805-8
[6] Becker, K., Langer, R., Reim, D., et al. (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases. Annals of Surgery, 253, 934-939.
http://dx.doi.org/10.1097/SLA.0b013e318216f449
[7] 王瑾, 曲秀娟, 滕月娥, 等 (2013) 卡培他滨联合多西紫杉醇一线治疗晚期的临床观察. 临床肿瘤学杂志, 5, 442-444.
[8] Miyazaki, S., Kimura, Y., Danno, K., et al. (2011) S 1 treatment for elderly patients over 75 years with gastric cancer. Gan To Kagaku Ryoho, 38, 581-584.
[9] Nio, Y., Koike, M., Omori, H., et al. (2004) A randomized consent design trial of neoadjuvant chemotherapy with tegafurplusuracil (UFT) for gastric cancer—A single institute study. Anticancer Research, 24, 1879-1887.
[10] 董平, 顾钧, 陆建华, 等 (2009) 进展期胃癌新辅助化疗的临床研究. 浙江临床医学, 8, 807-808.
[11] Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine, 355, 11-20.
http://dx.doi.org/10.1056/NEJMoa055531
[12] Boige, V., Pignon, J., Saint-Aubert, B., et al. (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE). American Society of Clinical Oncology, 25, 4510.
[13] Opitz, I., Kestenholz, P., Lardinois, D., et al. (2006) Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. European Journal Cardio-Thoracic Surgery, 29, 579-584.
http://dx.doi.org/10.1016/j.ejcts.2006.01.015
[14] Earle, C.C., Maroun, J. and Zuraw, L. (2002) Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group. Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline. Canadian Journal of Surgery, 45, 438-446.
[15] Stein, H.J., Feith, M. and Siewert, J.R. (2000) Cancer of the esophagogastric junction. Surgical Oncology, 9, 35-41.
http://dx.doi.org/10.1016/S0960-7404(00)00021-9